Replies to post #360774 on Innovation Pharmaceuticals Inc (IPIX)

[leavetheguntakethecannolis]

As the days wind down to trial results it would appear the detractors are throwing the kitchen sink trying to shake a few shares loose. Nice try.

[farrell90]

Sotrovimab is a monoclonal antibody which attaches to the Spike protein of the Coronavirus.

This is the same site of attachment as the other Covid 19 monoclonal antibodies, baricitinib, bamlanivimab,as well as Regeneron's antibiotic cocktail of casirivimab and imdevimab; all have been given an EUAs but have not approved as Covid 19 therapeutics.

The other monoclonal antibodies for Covid all block viral entry into the human cells to prevent infection. Sotrovimab also blocks viral cell entry, but its mechanism is defined in a more detailed manner:
"Sotrovimab inhibits an undefined step that occurs after virus attachment and prior to fusion of the viral and cell membranes."

"Sotrovimab is a recombinant human IgG1-kappa mAb that binds to a conserved epitope on the spike protein receptor binding domain of SARS-CoV-2 with a dissociation constant KD = 0.21 nM) but does not compete with human ACE2 receptor binding (IC50 value >33.6 nM [5 µg/mL]). Sotrovimab inhibits an undefined step that occurs after virus attachment and prior to fusion of the viral and cell membranes. The Fc domain of sotrovimab includes M428L and N434S amino acid substitutions (LS modification) that extend antibody half-life, but do not impact wild-type Fc-mediated effector functions in cell culture."

The FDA seems concerned Sotrovimab will share so of the other Covid 19 monoclonal antibody side effects and listed them in the physicians insert as a warning to doctors treating Covid19 patients.

"5.2 Clinical Worsening After SARS-CoV-2 Monoclonal Antibody AdministrationClinical worsening of COVID-19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrythmia (e.g., atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of
Covid19"

GLTA, Farrell